Peptide Library / Detail
ACE-031
Half-life
Approximately 10–15 days (human PK, single-dose SC)
Delivery
Subcutaneous injection; historical clinical protocols dosed every 2–4 weeks.
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
ACE-031 (ActRIIB-Fc Ligand Trap) is a recombinant fusion protein consisting of the extracellular domain of activin receptor type IIB (ActRIIB) linked to an IgG1 Fc fragment. It serves as a decoy receptor that binds myostatin (GDF8) and related ligands (e.g., activins), thereby reducing SMAD2/3 signaling to promote muscle and bone anabolism in research settings.
Usage
Used to study muscle-wasting disorders, sarcopenia/cachexia models, bone mass regulation, and downstream metabolic/functional outcomes (lean mass, strength, BMD).
Mechanism of Action
Ligand trap that sequesters myostatin and select activins from ActRIIA/B receptors, attenuating TGF-β/SMAD2/3 signaling; results include increased muscle protein synthesis/hypertrophy and bone accrual.
Benefits(3)
- Increases lean body mass and muscle volume in human and animal studies
- May improve functional measures (e.g., 6-minute walk trends in DMD studies)
- Associated increases in bone mineral density in some models
Side Effects(3)
- Epistaxis (nosebleeds) and telangiectasias reported in clinical studies
- Injection-site reactions (pain, pruritus, hematoma)
- Potential vascular effects linked to broader ligand binding (e.g., BMP9/10 cross-reactivity in class)
ACE-031 — frequently asked questions
What is ACE-031?
ACE-031 (ActRIIB-Fc Ligand Trap) is a recombinant fusion protein consisting of the extracellular domain of activin receptor type IIB (ActRIIB) linked to an IgG1 Fc fragment. It serves as a decoy receptor that binds myostatin (GDF8) and related ligands (e.g., activins), thereby reducing SMAD2/3 signaling to promote muscle and bone anabolism in research settings.
What is the half-life of ACE-031?
ACE-031 has an approximate half-life of Approximately 10–15 days (human PK, single-dose SC). The half-life determines how often you need to inject to maintain steady blood levels — use the Peptides Calculator half-life calculator to plot your specific dosing schedule and see the decay curve.
How is ACE-031 administered?
ACE-031 is typically delivered via subcutaneous injection; historical clinical protocols dosed every 2–4 weeks.. The Peptides Calculator app helps you reconstitute the vial with bacteriostatic water, calculate your exact dose in syringe units, and track each injection.
How does ACE-031 work?
Ligand trap that sequesters myostatin and select activins from ActRIIA/B receptors, attenuating TGF-β/SMAD2/3 signaling; results include increased muscle protein synthesis/hypertrophy and bone accrual.
What are the researched benefits of ACE-031?
Studied benefits of ACE-031 include: Increases lean body mass and muscle volume in human and animal studies, May improve functional measures (e.g., 6-minute walk trends in DMD studies), Associated increases in bone mineral density in some models. These are research findings only — Peptides Calculator does not provide medical advice; consult a qualified healthcare professional before starting any peptide protocol.
What are the side effects of ACE-031?
Reported side effects of ACE-031 include: Epistaxis (nosebleeds) and telangiectasias reported in clinical studies, Injection-site reactions (pain, pruritus, hematoma), Potential vascular effects linked to broader ligand binding (e.g., BMP9/10 cross-reactivity in class). Always discuss potential side effects with a licensed healthcare provider before using any research peptide.